Global Prostate Cancer Nuclear Medicine Diagnostics Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2022 –2029 |
Market Size (Base Year) |
USD 389.14 Million |
Market Size (Forecast Year) |
USD 1,024.35 Million |
CAGR |
|
Major Markets Players |
|
>全球前列腺癌核医学诊断市场,按类型(单光子发射计算机断层扫描 (SPECT)和光子发射计算机断层扫描 (PET))、产品(F-18、C11 和 GA 68 PSMA)、应用(医院、诊所和其他)划分 - 行业趋势和预测到 2029 年。
前列腺癌核医学诊断市场分析及规模
核医学广泛应用于癌症治疗和骨转移的放射性药物应用。与X射线和其他外部放射成像设备相比,它不仅对医生的诊断有用,而且对患者来说也是一种方便安全的替代方法。诊断程序中使用的核医学包括F-18、Tc-99、Ga-67和I-123,而治疗程序包括I-131、Ir-192、Y-90、I-125和Lu-177。
Data Bridge Market Research 分析,前列腺癌核医学诊断市场在 2021 年为 3.8914 亿美元,预计到 2029 年将达到 10.2435 亿美元,在 2022 年至 2029 年的预测期内复合年增长率为 11.7%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
前列腺癌核医学诊断市场范围和细分
报告指标 |
细节 |
预测期 |
2022 至 2029 年 |
基准年 |
2021 |
历史岁月 |
2020(可定制为 2014 - 2019) |
定量单位 |
收入(百万美元)、销量(单位)、定价(美元) |
涵盖的领域 |
类型(单光子发射计算机断层扫描 (SPECT) 和光子发射计算机断层扫描 (PET))、产品(F-18、C11 和 GA 68 PSMA)、应用(医院、诊所和其他) |
覆盖国家 |
北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲的其他地区。 |
涵盖的市场参与者 |
|
Market Opportunities |
|
Market Definition
Prostate cancer affects the prostate glands in men. Prostate cancer is the second most common cancer in men after skin cancer. Family history, advanced age, and race are all common risk factors for prostate cancer. Nuclear medicine is imaging that requires radioactive materials. It is an effective method for detecting and treating prostate cancer and it assists radiologists in determining the stage of the disease. Prostate cancer nuclear medicine diagnostics is a useful method to detect and treat prostate cancer and helps radiologists to figure out the stage of cancer.
Global Prostate Cancer Nuclear Medicine Diagnostics Market Dynamics
Drivers
- Surging demand for early and precise diagnosis of prostate cancer
An increase in PSA levels raises the risk of prostate cancer. PSA concentrations in the blood are measured in nanograms per millilitre (ng/mL). There is no clear cut-off point for determining whether a man has prostate cancer or not. Many doctors use a PSA cut-off of 4 ng/mL or higher when determining whether a man requires further testing, while others may be starting at a lower level, such as 2.5 or 3. As a result, measuring PSA levels in a man's blood can help detect prostate cancer early. These are the certain factors which propel the growth of the market.
- Increasing demand for positron emission tomography
Positron emission tomography is increasingly being used as a diagnostic tool because it is more accurate than other diagnostic techniques. The accuracy of diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to drive the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies are expected to accelerate the development of nuclear medicine diagnostics.
Opportunities
- Government initiatives bolstering growth and awareness
Several programs in the United States, such as Medicaid, Medicare, and Health Insurance, are expected to create growth opportunities for market participants. For instance, the Centers for Medicare & Medicaid Services (CMS) covers positron emission tomography services through the National Coverage Determination (NCD), which includes tracers required for prostate cancer diagnosis. As a result of these factors, positron emission tomography is expected to have the largest market share.
Restraints/Challenges
- High cost of prostate cancer
High cost of prostate cancer nuclear medicine diagnostics and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. There are health risks, because radiation is a side effect of nuclear medicine, prolonged exposure to it can cause health problems. This is especially true for infants, toddlers, elderly and pregnant women.
This prostate cancer nuclear medicine diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer nuclear medicine diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In April 2022, Telix announced that Illuccix (kit for the preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, will be commercially available in the United States.
- In March 2022, Novartis announced that the FDA had approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (formerly known as 177Lu-PSMA-617) for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that has spread to other parts of the body (metastatic).
Global Prostate Cancer Nuclear Medicine Diagnostics Market Scope
The prostate cancer nuclear medicine diagnostics market is segmented on the basis of product, type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market.
Type
- Single Photon Emission Computed Tomography (SPECT)
- Photon Emission Computed Tomography (PET)
Product
- F-18
- C11
- GA 68 PSMA
Application
- Hospitals
- Clinics
- Others
Prostate Cancer Nuclear Medicine Diagnostics Market Regional Analysis/Insights
对前列腺癌核医学诊断市场进行了分析,并按国家、产品、类型和应用提供了市场规模见解和趋势。
前列腺癌核医学诊断市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于该地区医疗保健基础设施的改善,北美在前列腺癌核医学诊断市场占据主导地位。
由于膀胱癌、食道癌、肝癌、胰腺癌等癌症的发病率不断增加,以及美国各大制造商的广泛存在,此外,技术进步和外国投资不断增加,预计亚太地区将在 2022 年至 2029 年的预测期内以最高的增长率增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
前列腺癌核医学诊断市场还为您提供了每个国家/地区资本设备医疗支出增长、前列腺癌核医学诊断市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对前列腺癌核医学诊断市场的影响的详细市场分析。数据适用于 2010-2020 年的历史时期。
竞争格局和前列腺癌核医学诊断市场份额分析
前列腺癌核医学诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对前列腺癌核医学诊断市场的关注有关。
前列腺癌核医学诊断市场的一些主要参与者包括:
- Blue Earth Diagnostics(英国)
- Lantheus(美国)
- Theragnostics Ltd(英国)
- Jubilant Pharma Limited(美国)
- NCM-USA LLC(美国)
- Telix Pharmaceuticals Ltd(澳大利亚)
- 康德乐 (美国)
- 通用电气(美国)
- Lantheus(美国)
- 拜耳公司(德国)
- 博莱科诊断公司(意大利)
- NorthStar Medical Radioisotopes, LLC(美国)
- 埃克特和齐格勒(德国)
- Jubilant DraxImage, Inc.(加拿大)
- PharmaLogic Holdings Corp.(美国)
- 匈牙利同位素研究所有限公司
- SHINE Medical Technologies, LLC(美国)
- 全球医疗解决方案有限责任公司 (中国)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.